Targeted proteomics strategy applied to biomarker evaluation |
| |
Authors: | Yeoun Jin Kim Sebastien Gallien Jan van Oostrum Bruno Domon |
| |
Affiliation: | 1. Luxembourg Clinical Proteomics Center, CRP-Santé, Strassen, Luxembourg;2. Luxembourg Clinical Proteomics Center, CRP-Santé, Strassen, Luxembourg
Correspondence: Prof. Dr. Bruno Domon, Luxembourg Clinical Proteomics Center (LCP), CRP-Santé, 1-A, rue Thomas Edison, Strassen, 1445, Luxembourg
E-mail:bdomon@crp-sante.lu
Fax: +35226970717 |
| |
Abstract: | The evaluation of biomarker candidates, involving quantitative measurement of a large number of proteins in bodily fluids, remains the main obstruction in the development of a biomarker validation pipeline. Although immunoassays are commonly used, high-throughput and multiplex-capable methods are required for expediting the evaluation process. MS-based approaches employing targeted proteomic strategies provide not only a sensitive, but in addition a precise quantification tool, which is versatile, systematic, and scalable. Its capability of multiplexing hundreds of targets facilitate a cost-effective and rapid evaluation and is especially useful during the early stage of the process where a large list of candidate biomarkers must be triaged before entering validation studies. The robustness requirement for the methods also mandates a high degree of selectivity to analyze complex clinical samples. Improvement in the selectivity of LC-MS methods has been achieved by adopting high-resolution and high-accuracy mass analyzers to perform quantitative analyses with a novel method called parallel reaction monitoring. This article discusses the design and performance of biomarker evaluation studies using targeted proteomics strategies and the implementation of recent technology developments. |
| |
Keywords: | Parallel reaction monitoring Targeted proteomics |
|
|